首页   >  

所有产品分类

所有产品

信号通路

研究领域

天然产物

抗体

多肽

催化剂

杂质对照品

医药中间体

基础原料

Jak/Stat Pathway

结构式 货号 产品名称 CAS号
PF-06459988 结构式
BCP44108 PF-06459988 1428774-45-1
PF-06459988 is an orally available, small molecule, third-generation, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant (EGFRm) forms with potential antineoplastic activity.
Ilginatinib 结构式
BCP44119 Ilginatinib 1239358-86-1
Ilginatinib is an orally bioavailable, small molecule inhibitor of Janus-associated kinase 2 (JAK2) and Src-family kinases, with potential antineoplastic activity. JAK2/Src inhibitor NS-018 competes with ATP for binding to JAK2 as well as the mutated form JAK2V617F, thereby inhibiting the activation of JAK2 and downstream molecules in the JAK2/STAT3 (signal transducer and activator of transcription 3) signaling pathway that plays an important role in normal development, particularly hematopoiesis. In addition, NS-018 inhibits the Src family tyrosine kinases. This eventually leads to the induction of tumor cell apoptosis.
STAT3-IN-3 结构式
BCP43810 STAT3-IN-3 2361304-26-7
STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3).
PIM1-IN-1 结构式
BCP43782 PIM1-IN-1 1417630-95-5
PIM1-IN-1 is a potent and highly selective inhibitor of PIM1/3(IC50s of 7, 5530 and 70 nM for PIM1, PIM2, and PIM3, respectively),with Antiproliferative and anti-cancer activity.
AZ7550 hydrochloride 结构式
BCP43207 AZ7550 hydrochloride 2309762-40-9
AZ-7550 is a metabolite of Osimertinib.
Aurora B inhibitor 1 结构式
BCP42843 Aurora B抑制剂1 937276-52-3
Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor extracted from patent WO2007059299A1, compound 1-3, has a Ki value of <0.010 uM.
STAT3-IN-1 结构式
BCP42674 STAT3-IN-1 2059952-75-7
STAT3-IN-1 is a novel selective and orally active STAT3 inhibitor.
BD750 结构式
BCP42671 BD750 892686-59-8
BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively.
Parsaclisib hydrochloride 结构式
BCP42656 Parsaclisib hydrochloride 1995889-48-9
Parsaclisib, also known as INCB050465, is a novel PI3Kδ inhibitor which synergizes with PIM protein kinase inhibition to cause tumor regression in a model of DLBCL.
SB1317 结构式
BCP42651 SB1317 1204918-72-8
SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. Zotiraciclib may be useful for the treatment of cancer that crosses the blood brain barrier and acts by depleting Myc through the inhibition of cyclin-dependent kinase 9 (CDK9). It is one of a number of CDK inhibitors under investigation; others targeting CDK9 for the treatment of acute myeloid leukemia include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80 percent of glioblastomas characterized by this property.
123下一页末页共 263 条记录 1 / 27 页 
2853530910